 | • レポートコード：MRC2Q12-19460 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、88ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、ウイルス性関節炎ワクチンの世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にウイルス性関節炎ワクチンのグローバル市場のxxx％を占める「ウイルス性関節炎ワクチン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「農場」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 ウイルス性関節炎ワクチンの中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのウイルス性関節炎ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 ウイルス性関節炎ワクチンのグローバル主要プレイヤーには、Pfizer、Dahuanong、Lohmann Animal Health、Yebio、MSDなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ウイルス性関節炎ワクチン市場は、種類と用途によって区分されます。世界のウイルス性関節炎ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 ウイルス性関節炎ワクチン、生、ウイルス性関節炎ワクチン、不活化 【用途別セグメント】 農場、個人 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ウイルス性関節炎ワクチン製品概要 - 種類別市場（ウイルス性関節炎ワクチン、生、ウイルス性関節炎ワクチン、不活化） - 用途別市場（農場、個人） - 調査の目的 ・エグゼクティブサマリー - 世界のウイルス性関節炎ワクチン販売量予測2017-2028 - 世界のウイルス性関節炎ワクチン売上予測2017-2028 - ウイルス性関節炎ワクチンの地域別販売量 - ウイルス性関節炎ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ウイルス性関節炎ワクチン販売量 - 主要メーカー別ウイルス性関節炎ワクチン売上 - 主要メーカー別ウイルス性関節炎ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（ウイルス性関節炎ワクチン、生、ウイルス性関節炎ワクチン、不活化） - ウイルス性関節炎ワクチンの種類別販売量 - ウイルス性関節炎ワクチンの種類別売上 - ウイルス性関節炎ワクチンの種類別価格 ・用途別市場規模（農場、個人） - ウイルス性関節炎ワクチンの用途別販売量 - ウイルス性関節炎ワクチンの用途別売上 - ウイルス性関節炎ワクチンの用途別価格 ・北米市場 - 北米のウイルス性関節炎ワクチン市場規模（種類別、用途別） - 主要国別のウイルス性関節炎ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのウイルス性関節炎ワクチン市場規模（種類別、用途別） - 主要国別のウイルス性関節炎ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のウイルス性関節炎ワクチン市場規模（種類別、用途別） - 主要国別のウイルス性関節炎ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のウイルス性関節炎ワクチン市場規模（種類別、用途別） - 主要国別のウイルス性関節炎ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのウイルス性関節炎ワクチン市場規模（種類別、用途別） - 主要国別のウイルス性関節炎ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer、Dahuanong、Lohmann Animal Health、Yebio、MSD ・産業チェーン及び販売チャネル分析 - ウイルス性関節炎ワクチンの産業チェーン分析 - ウイルス性関節炎ワクチンの原材料 - ウイルス性関節炎ワクチンの生産プロセス - ウイルス性関節炎ワクチンの販売及びマーケティング - ウイルス性関節炎ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ウイルス性関節炎ワクチンの産業動向 - ウイルス性関節炎ワクチンのマーケットドライバー - ウイルス性関節炎ワクチンの課題 - ウイルス性関節炎ワクチンの阻害要因 ・主な調査結果 |
Biological products used to prevent arthritis in chickens
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Viral Arthritis Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Viral Arthritis Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Viral Arthritis Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Viral Arthritis Vaccine include Pfizer, Dahuanong, Lohmann Animal Health, Yebio and MSD, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Viral Arthritis Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Viral Arthritis Vaccine market. Further, it explains the major drivers and regional dynamics of the global Viral Arthritis Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer
Dahuanong
Lohmann Animal Health
Yebio
MSD
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by activity and by downstream segments based on sales, price, and value for the period 2017-2028.
Viral Arthritis Vaccine Segment by Activity
Viral Arthritis Vaccine, Live
Viral Arthritis Vaccine, Inactivated
Viral Arthritis Vaccine Segment by Downstream
Farms
Individual
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Viral Arthritis Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Viral Arthritis Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Viral Arthritis Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Viral Arthritis Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Arthritis Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Viral Arthritis Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Viral Arthritis Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Dahuanong, Lohmann Animal Health, Yebio and MSD, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Viral Arthritis Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Viral Arthritis Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by activity, by downstream and by country, sales and revenue for each segment.
Chapter 7: Europe by activity, by downstream and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by activity, by downstream and by country, sales and revenue for each segment.
Chapter 9: Latin America by activity, by downstream and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by activity, by downstream and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Arthritis Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Viral Arthritis Vaccine Product Introduction
1.2 Market by Activity
1.2.1 Global Viral Arthritis Vaccine Market Size Growth Rate by Activity, 2017 VS 2021 VS 2028
1.2.2 Viral Arthritis Vaccine, Live
1.2.3 Viral Arthritis Vaccine, Inactivated
1.3 Market by Downstream
1.3.1 Global Viral Arthritis Vaccine Market Size Growth Rate by Downstream, 2017 VS 2021 VS 2028
1.3.2 Farms
1.3.3 Individual
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Viral Arthritis Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Viral Arthritis Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Viral Arthritis Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Viral Arthritis Vaccine Sales by Region
2.4.1 Global Viral Arthritis Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Viral Arthritis Vaccine by Region (2023-2028)
2.5 Global Viral Arthritis Vaccine Revenue by Region
2.5.1 Global Viral Arthritis Vaccine Revenue by Region (2017-2022)
2.5.2 Global Viral Arthritis Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Viral Arthritis Vaccine Sales by Manufacturers
3.1.1 Global Top Viral Arthritis Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Viral Arthritis Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Viral Arthritis Vaccine in 2021
3.2 Global Viral Arthritis Vaccine Revenue by Manufacturers
3.2.1 Global Viral Arthritis Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Viral Arthritis Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Viral Arthritis Vaccine Revenue in 2021
3.3 Global Viral Arthritis Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Viral Arthritis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Viral Arthritis Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Activity
4.1 Global Viral Arthritis Vaccine Sales by Activity
4.1.1 Global Viral Arthritis Vaccine Historical Sales by Activity (2017-2022)
4.1.2 Global Viral Arthritis Vaccine Forecasted Sales by Activity (2023-2028)
4.1.3 Global Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
4.2 Global Viral Arthritis Vaccine Revenue by Activity
4.2.1 Global Viral Arthritis Vaccine Historical Revenue by Activity (2017-2022)
4.2.2 Global Viral Arthritis Vaccine Forecasted Revenue by Activity (2023-2028)
4.2.3 Global Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
4.3 Global Viral Arthritis Vaccine Price by Activity
4.3.1 Global Viral Arthritis Vaccine Price by Activity (2017-2022)
4.3.2 Global Viral Arthritis Vaccine Price Forecast by Activity (2023-2028)
5 Market Size by Downstream
5.1 Global Viral Arthritis Vaccine Sales by Downstream
5.1.1 Global Viral Arthritis Vaccine Historical Sales by Downstream (2017-2022)
5.1.2 Global Viral Arthritis Vaccine Forecasted Sales by Downstream (2023-2028)
5.1.3 Global Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
5.2 Global Viral Arthritis Vaccine Revenue by Downstream
5.2.1 Global Viral Arthritis Vaccine Historical Revenue by Downstream (2017-2022)
5.2.2 Global Viral Arthritis Vaccine Forecasted Revenue by Downstream (2023-2028)
5.2.3 Global Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
5.3 Global Viral Arthritis Vaccine Price by Downstream
5.3.1 Global Viral Arthritis Vaccine Price by Downstream (2017-2022)
5.3.2 Global Viral Arthritis Vaccine Price Forecast by Downstream (2023-2028)
6 North America
6.1 North America Viral Arthritis Vaccine Market Size by Activity
6.1.1 North America Viral Arthritis Vaccine Sales by Activity (2017-2028)
6.1.2 North America Viral Arthritis Vaccine Revenue by Activity (2017-2028)
6.2 North America Viral Arthritis Vaccine Market Size by Downstream
6.2.1 North America Viral Arthritis Vaccine Sales by Downstream (2017-2028)
6.2.2 North America Viral Arthritis Vaccine Revenue by Downstream (2017-2028)
6.3 North America Viral Arthritis Vaccine Market Size by Country
6.3.1 North America Viral Arthritis Vaccine Sales by Country (2017-2028)
6.3.2 North America Viral Arthritis Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Viral Arthritis Vaccine Market Size by Activity
7.1.1 Europe Viral Arthritis Vaccine Sales by Activity (2017-2028)
7.1.2 Europe Viral Arthritis Vaccine Revenue by Activity (2017-2028)
7.2 Europe Viral Arthritis Vaccine Market Size by Downstream
7.2.1 Europe Viral Arthritis Vaccine Sales by Downstream (2017-2028)
7.2.2 Europe Viral Arthritis Vaccine Revenue by Downstream (2017-2028)
7.3 Europe Viral Arthritis Vaccine Market Size by Country
7.3.1 Europe Viral Arthritis Vaccine Sales by Country (2017-2028)
7.3.2 Europe Viral Arthritis Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Viral Arthritis Vaccine Market Size by Activity
8.1.1 Asia Pacific Viral Arthritis Vaccine Sales by Activity (2017-2028)
8.1.2 Asia Pacific Viral Arthritis Vaccine Revenue by Activity (2017-2028)
8.2 Asia Pacific Viral Arthritis Vaccine Market Size by Downstream
8.2.1 Asia Pacific Viral Arthritis Vaccine Sales by Downstream (2017-2028)
8.2.2 Asia Pacific Viral Arthritis Vaccine Revenue by Downstream (2017-2028)
8.3 Asia Pacific Viral Arthritis Vaccine Market Size by Region
8.3.1 Asia Pacific Viral Arthritis Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Viral Arthritis Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Viral Arthritis Vaccine Market Size by Activity
9.1.1 Latin America Viral Arthritis Vaccine Sales by Activity (2017-2028)
9.1.2 Latin America Viral Arthritis Vaccine Revenue by Activity (2017-2028)
9.2 Latin America Viral Arthritis Vaccine Market Size by Downstream
9.2.1 Latin America Viral Arthritis Vaccine Sales by Downstream (2017-2028)
9.2.2 Latin America Viral Arthritis Vaccine Revenue by Downstream (2017-2028)
9.3 Latin America Viral Arthritis Vaccine Market Size by Country
9.3.1 Latin America Viral Arthritis Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Viral Arthritis Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Viral Arthritis Vaccine Market Size by Activity
10.1.1 Middle East and Africa Viral Arthritis Vaccine Sales by Activity (2017-2028)
10.1.2 Middle East and Africa Viral Arthritis Vaccine Revenue by Activity (2017-2028)
10.2 Middle East and Africa Viral Arthritis Vaccine Market Size by Downstream
10.2.1 Middle East and Africa Viral Arthritis Vaccine Sales by Downstream (2017-2028)
10.2.2 Middle East and Africa Viral Arthritis Vaccine Revenue by Downstream (2017-2028)
10.3 Middle East and Africa Viral Arthritis Vaccine Market Size by Country
10.3.1 Middle East and Africa Viral Arthritis Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Viral Arthritis Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Viral Arthritis Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 Dahuanong
11.2.1 Dahuanong Corporation Information
11.2.2 Dahuanong Overview
11.2.3 Dahuanong Viral Arthritis Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Dahuanong Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Dahuanong Recent Developments
11.3 Lohmann Animal Health
11.3.1 Lohmann Animal Health Corporation Information
11.3.2 Lohmann Animal Health Overview
11.3.3 Lohmann Animal Health Viral Arthritis Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Lohmann Animal Health Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Lohmann Animal Health Recent Developments
11.4 Yebio
11.4.1 Yebio Corporation Information
11.4.2 Yebio Overview
11.4.3 Yebio Viral Arthritis Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Yebio Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Yebio Recent Developments
11.5 MSD
11.5.1 MSD Corporation Information
11.5.2 MSD Overview
11.5.3 MSD Viral Arthritis Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 MSD Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 MSD Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Viral Arthritis Vaccine Industry Chain Analysis
12.2 Viral Arthritis Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Viral Arthritis Vaccine Production Mode & Process
12.4 Viral Arthritis Vaccine Sales and Marketing
12.4.1 Viral Arthritis Vaccine Sales Channels
12.4.2 Viral Arthritis Vaccine Distributors
12.5 Viral Arthritis Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Viral Arthritis Vaccine Industry Trends
13.2 Viral Arthritis Vaccine Market Drivers
13.3 Viral Arthritis Vaccine Market Challenges
13.4 Viral Arthritis Vaccine Market Restraints
14 Key Findings in The Global Viral Arthritis Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Viral Arthritis Vaccine Market Size Growth Rate by Activity, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Viral Arthritis Vaccine, Live
Table 3. Major Manufacturers of Viral Arthritis Vaccine, Inactivated
Table 4. Global Viral Arthritis Vaccine Market Size Growth Rate by Downstream, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Viral Arthritis Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Viral Arthritis Vaccine Sales by Region (2017-2022) & (Box)
Table 7. Global Viral Arthritis Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Viral Arthritis Vaccine Sales by Region (2023-2028) & (Box)
Table 9. Global Viral Arthritis Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Viral Arthritis Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Viral Arthritis Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Viral Arthritis Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Viral Arthritis Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Viral Arthritis Vaccine Sales by Manufacturers (2017-2022) & (Box)
Table 15. Global Viral Arthritis Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Viral Arthritis Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Viral Arthritis Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Viral Arthritis Vaccine Price by Manufacturers (2017-2022) &(US$/Box)
Table 19. Global Viral Arthritis Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Viral Arthritis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Arthritis Vaccine as of 2021)
Table 21. Viral Arthritis Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Viral Arthritis Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Viral Arthritis Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Viral Arthritis Vaccine Sales by Activity (2017-2022) & (Box)
Table 26. Global Viral Arthritis Vaccine Sales by Activity (2023-2028) & (Box)
Table 27. Global Viral Arthritis Vaccine Sales Share by Activity (2017-2022)
Table 28. Global Viral Arthritis Vaccine Sales Share by Activity (2023-2028)
Table 29. Global Viral Arthritis Vaccine Revenue by Activity (2017-2022) & (US$ Million)
Table 30. Global Viral Arthritis Vaccine Revenue by Activity (2023-2028) & (US$ Million)
Table 31. Global Viral Arthritis Vaccine Revenue Share by Activity (2017-2022)
Table 32. Global Viral Arthritis Vaccine Revenue Share by Activity (2023-2028)
Table 33. Viral Arthritis Vaccine Price by Activity (2017-2022) & (US$/Box)
Table 34. Global Viral Arthritis Vaccine Price Forecast by Activity (2023-2028) & (US$/Box)
Table 35. Global Viral Arthritis Vaccine Sales by Downstream (2017-2022) & (Box)
Table 36. Global Viral Arthritis Vaccine Sales by Downstream (2023-2028) & (Box)
Table 37. Global Viral Arthritis Vaccine Sales Share by Downstream (2017-2022)
Table 38. Global Viral Arthritis Vaccine Sales Share by Downstream (2023-2028)
Table 39. Global Viral Arthritis Vaccine Revenue by Downstream (2017-2022) & (US$ Million)
Table 40. Global Viral Arthritis Vaccine Revenue by Downstream (2023-2028) & (US$ Million)
Table 41. Global Viral Arthritis Vaccine Revenue Share by Downstream (2017-2022)
Table 42. Global Viral Arthritis Vaccine Revenue Share by Downstream (2023-2028)
Table 43. Viral Arthritis Vaccine Price by Downstream (2017-2022) & (US$/Box)
Table 44. Global Viral Arthritis Vaccine Price Forecast by Downstream (2023-2028) & (US$/Box)
Table 45. North America Viral Arthritis Vaccine Sales by Activity (2017-2022) & (Box)
Table 46. North America Viral Arthritis Vaccine Sales by Activity (2023-2028) & (Box)
Table 47. North America Viral Arthritis Vaccine Revenue by Activity (2017-2022) & (US$ Million)
Table 48. North America Viral Arthritis Vaccine Revenue by Activity (2023-2028) & (US$ Million)
Table 49. North America Viral Arthritis Vaccine Sales by Downstream (2017-2022) & (Box)
Table 50. North America Viral Arthritis Vaccine Sales by Downstream (2023-2028) & (Box)
Table 51. North America Viral Arthritis Vaccine Revenue by Downstream (2017-2022) & (US$ Million)
Table 52. North America Viral Arthritis Vaccine Revenue by Downstream (2023-2028) & (US$ Million)
Table 53. North America Viral Arthritis Vaccine Sales by Country (2017-2022) & (Box)
Table 54. North America Viral Arthritis Vaccine Sales by Country (2023-2028) & (Box)
Table 55. North America Viral Arthritis Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Viral Arthritis Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Viral Arthritis Vaccine Sales by Activity (2017-2022) & (Box)
Table 58. Europe Viral Arthritis Vaccine Sales by Activity (2023-2028) & (Box)
Table 59. Europe Viral Arthritis Vaccine Revenue by Activity (2017-2022) & (US$ Million)
Table 60. Europe Viral Arthritis Vaccine Revenue by Activity (2023-2028) & (US$ Million)
Table 61. Europe Viral Arthritis Vaccine Sales by Downstream (2017-2022) & (Box)
Table 62. Europe Viral Arthritis Vaccine Sales by Downstream (2023-2028) & (Box)
Table 63. Europe Viral Arthritis Vaccine Revenue by Downstream (2017-2022) & (US$ Million)
Table 64. Europe Viral Arthritis Vaccine Revenue by Downstream (2023-2028) & (US$ Million)
Table 65. Europe Viral Arthritis Vaccine Sales by Country (2017-2022) & (Box)
Table 66. Europe Viral Arthritis Vaccine Sales by Country (2023-2028) & (Box)
Table 67. Europe Viral Arthritis Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Viral Arthritis Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Viral Arthritis Vaccine Sales by Activity (2017-2022) & (Box)
Table 70. Asia Pacific Viral Arthritis Vaccine Sales by Activity (2023-2028) & (Box)
Table 71. Asia Pacific Viral Arthritis Vaccine Revenue by Activity (2017-2022) & (US$ Million)
Table 72. Asia Pacific Viral Arthritis Vaccine Revenue by Activity (2023-2028) & (US$ Million)
Table 73. Asia Pacific Viral Arthritis Vaccine Sales by Downstream (2017-2022) & (Box)
Table 74. Asia Pacific Viral Arthritis Vaccine Sales by Downstream (2023-2028) & (Box)
Table 75. Asia Pacific Viral Arthritis Vaccine Revenue by Downstream (2017-2022) & (US$ Million)
Table 76. Asia Pacific Viral Arthritis Vaccine Revenue by Downstream (2023-2028) & (US$ Million)
Table 77. Asia Pacific Viral Arthritis Vaccine Sales by Region (2017-2022) & (Box)
Table 78. Asia Pacific Viral Arthritis Vaccine Sales by Region (2023-2028) & (Box)
Table 79. Asia Pacific Viral Arthritis Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Viral Arthritis Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Viral Arthritis Vaccine Sales by Activity (2017-2022) & (Box)
Table 82. Latin America Viral Arthritis Vaccine Sales by Activity (2023-2028) & (Box)
Table 83. Latin America Viral Arthritis Vaccine Revenue by Activity (2017-2022) & (US$ Million)
Table 84. Latin America Viral Arthritis Vaccine Revenue by Activity (2023-2028) & (US$ Million)
Table 85. Latin America Viral Arthritis Vaccine Sales by Downstream (2017-2022) & (Box)
Table 86. Latin America Viral Arthritis Vaccine Sales by Downstream (2023-2028) & (Box)
Table 87. Latin America Viral Arthritis Vaccine Revenue by Downstream (2017-2022) & (US$ Million)
Table 88. Latin America Viral Arthritis Vaccine Revenue by Downstream (2023-2028) & (US$ Million)
Table 89. Latin America Viral Arthritis Vaccine Sales by Country (2017-2022) & (Box)
Table 90. Latin America Viral Arthritis Vaccine Sales by Country (2023-2028) & (Box)
Table 91. Latin America Viral Arthritis Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Viral Arthritis Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Viral Arthritis Vaccine Sales by Activity (2017-2022) & (Box)
Table 94. Middle East and Africa Viral Arthritis Vaccine Sales by Activity (2023-2028) & (Box)
Table 95. Middle East and Africa Viral Arthritis Vaccine Revenue by Activity (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Viral Arthritis Vaccine Revenue by Activity (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Viral Arthritis Vaccine Sales by Downstream (2017-2022) & (Box)
Table 98. Middle East and Africa Viral Arthritis Vaccine Sales by Downstream (2023-2028) & (Box)
Table 99. Middle East and Africa Viral Arthritis Vaccine Revenue by Downstream (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Viral Arthritis Vaccine Revenue by Downstream (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Viral Arthritis Vaccine Sales by Country (2017-2022) & (Box)
Table 102. Middle East and Africa Viral Arthritis Vaccine Sales by Country (2023-2028) & (Box)
Table 103. Middle East and Africa Viral Arthritis Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Viral Arthritis Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Major Businesses
Table 107. Pfizer Viral Arthritis Vaccine Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 108. Pfizer Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Pfizer Recent Developments
Table 110. Dahuanong Corporation Information
Table 111. Dahuanong Description and Major Businesses
Table 112. Dahuanong Viral Arthritis Vaccine Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 113. Dahuanong Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Dahuanong Recent Developments
Table 115. Lohmann Animal Health Corporation Information
Table 116. Lohmann Animal Health Description and Major Businesses
Table 117. Lohmann Animal Health Viral Arthritis Vaccine Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 118. Lohmann Animal Health Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Lohmann Animal Health Recent Developments
Table 120. Yebio Corporation Information
Table 121. Yebio Description and Major Businesses
Table 122. Yebio Viral Arthritis Vaccine Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 123. Yebio Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Yebio Recent Developments
Table 125. MSD Corporation Information
Table 126. MSD Description and Major Businesses
Table 127. MSD Viral Arthritis Vaccine Sales (Box), Revenue (US$ Million), Price (US$/Box) and Gross Margin (2017-2022)
Table 128. MSD Viral Arthritis Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. MSD Recent Developments
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Viral Arthritis Vaccine Distributors List
Table 133. Viral Arthritis Vaccine Customers List
Table 134. Viral Arthritis Vaccine Market Trends
Table 135. Viral Arthritis Vaccine Market Drivers
Table 136. Viral Arthritis Vaccine Market Challenges
Table 137. Viral Arthritis Vaccine Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Arthritis Vaccine Product Picture
Figure 2. Global Viral Arthritis Vaccine Market Share by Activity in 2021 & 2028
Figure 3. Viral Arthritis Vaccine, Live Product Picture
Figure 4. Viral Arthritis Vaccine, Inactivated Product Picture
Figure 5. Global Viral Arthritis Vaccine Market Share by Downstream in 2021 & 2028
Figure 6. Farms
Figure 7. Individual
Figure 8. Viral Arthritis Vaccine Report Years Considered
Figure 9. Global Viral Arthritis Vaccine Sales 2017-2028 (Box)
Figure 10. Global Viral Arthritis Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Viral Arthritis Vaccine Revenue 2017-2028 (US$ Million)
Figure 12. Global Viral Arthritis Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Viral Arthritis Vaccine Sales Market Share by Region (2017-2022)
Figure 14. Global Viral Arthritis Vaccine Sales Market Share by Region (2023-2028)
Figure 15. North America Viral Arthritis Vaccine Sales YoY (2017-2028) & (Box)
Figure 16. North America Viral Arthritis Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Viral Arthritis Vaccine Sales YoY (2017-2028) & (Box)
Figure 18. Europe Viral Arthritis Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Viral Arthritis Vaccine Sales YoY (2017-2028) & (Box)
Figure 20. Asia-Pacific Viral Arthritis Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Viral Arthritis Vaccine Sales YoY (2017-2028) & (Box)
Figure 22. Latin America Viral Arthritis Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Viral Arthritis Vaccine Sales YoY (2017-2028) & (Box)
Figure 24. Middle East & Africa Viral Arthritis Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Viral Arthritis Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Viral Arthritis Vaccine in the World: Market Share by Viral Arthritis Vaccine Revenue in 2021
Figure 27. Global Viral Arthritis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
Figure 29. Global Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
Figure 30. Global Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
Figure 31. Global Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
Figure 32. North America Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
Figure 33. North America Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
Figure 34. North America Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
Figure 35. North America Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
Figure 36. North America Viral Arthritis Vaccine Sales Share by Country (2017-2028)
Figure 37. North America Viral Arthritis Vaccine Revenue Share by Country (2017-2028)
Figure 38. United States Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
Figure 41. Europe Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
Figure 42. Europe Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
Figure 43. Europe Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
Figure 44. Europe Viral Arthritis Vaccine Sales Share by Country (2017-2028)
Figure 45. Europe Viral Arthritis Vaccine Revenue Share by Country (2017-2028)
Figure 46. Germany Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 47. France Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
Figure 52. Asia Pacific Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
Figure 53. Asia Pacific Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
Figure 54. Asia Pacific Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
Figure 55. Asia Pacific Viral Arthritis Vaccine Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Viral Arthritis Vaccine Revenue Share by Region (2017-2028)
Figure 57. China Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. India Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. China Taiwan Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Latin America Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
Figure 67. Latin America Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
Figure 68. Latin America Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
Figure 69. Latin America Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
Figure 70. Latin America Viral Arthritis Vaccine Sales Share by Country (2017-2028)
Figure 71. Latin America Viral Arthritis Vaccine Revenue Share by Country (2017-2028)
Figure 72. Mexico Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 73. Brazil Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 74. Argentina Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 75. Middle East and Africa Viral Arthritis Vaccine Sales Market Share by Activity (2017-2028)
Figure 76. Middle East and Africa Viral Arthritis Vaccine Revenue Market Share by Activity (2017-2028)
Figure 77. Middle East and Africa Viral Arthritis Vaccine Sales Market Share by Downstream (2017-2028)
Figure 78. Middle East and Africa Viral Arthritis Vaccine Revenue Market Share by Downstream (2017-2028)
Figure 79. Middle East and Africa Viral Arthritis Vaccine Sales Share by Country (2017-2028)
Figure 80. Middle East and Africa Viral Arthritis Vaccine Revenue Share by Country (2017-2028)
Figure 81. Turkey Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 82. Saudi Arabia Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 83. UAE Viral Arthritis Vaccine Revenue (2017-2028) & (US$ Million)
Figure 84. Viral Arthritis Vaccine Value Chain
Figure 85. Viral Arthritis Vaccine Production Process
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed